← Leaderboards
Sanford D Markowitz
Case Western Reserve University
$49,710,196
Attributed
$64,662,504
Total exposure
29
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$102,731,221 · 31
By mechanism
P50$31,245,588 · 7
U01$21,379,910 · 4
U54$19,268,156 · 4
R01$19,169,063 · 9
R35$6,590,430 · 1
RM1$4,197,317 · 1
Top collaborators
- William M Grady18 shared
- Amitabh Chak16 shared
- Kishore Guda10 shared
- Nicholas J Shaheen10 shared
- Joseph M Ready9 shared
- Nathan A. Berger8 shared
- Andrew A Pieper5 shared
- Peter Christopher Scacheri5 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Nathan A. Berger$11,283,519
- Amar Desai$1,878,505
- Henri Brunengraber$19,168,451
- Zhenghe Wang$15,658,585
- Yeo Jung Koh$190,400
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBaseColon CarcinomaGenesCessation Of LifeEarly DiagnosisPreventionPathway InteractionsColonColonic NeoplasmsEsophageal AdenocarcinomaCancer EtiologyMolecularMutationProgramsDetectionGeneticBiological MarkersScreeningBarrett EsophagusResistanceTissuesIncidenceBiological
Grant awards (146)
A Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett's Esophagus and Its Progression$1,623,261
R01 · FY2025 · CA · contact PI
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,354,462
RM1 · FY2025 · GM
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,048,823
U01 · FY2025 · CA · contact PI
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,354,462
RM1 · FY2024 · GM
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$996,868
U01 · FY2024 · CA · contact PI
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$94,538
RM1 · FY2024 · GM
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$39,393
RM1 · FY2024 · GM
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,354,462
RM1 · FY2023 · GM
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,028,348
U01 · FY2023 · CA · contact PI
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment$931,980
R35 · FY2023 · CA · contact PI
GI Cancer Genetics Research Program$62,101
P30 · FY2023 · CA · contact PI
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment$931,980
R35 · FY2022 · CA · contact PI
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$781,052
U01 · FY2022 · CA · contact PI
Administrative Core$664,839
P50 · FY2022 · CA · contact PI
Case GI SPORE$664,839
P50 · FY2022 · CA · contact PI
GI Cancer Genetics Research Program$55,094
P30 · FY2022 · CA · contact PI
Case GI SPORE$2,324,999
P50 · FY2021 · CA · contact PI
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma$1,290,333
U54 · FY2021 · CA
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment$951,000
R35 · FY2021 · CA · contact PI
Biomarkers for Reducing Mortality of Cancers of the Colon and Esophagus$407,598
U01 · FY2021 · CA · contact PI
Project 2 - Molecular Markers for Barrett's Screening and Surveillance$283,277
U54 · FY2021 · CA · contact PI
Administrative Core$232,501
P50 · FY2021 · CA · contact PI
Project 1: Targeting 15-PGDH in Colon Cancer Risk, Prevention and Treatment$232,501
P50 · FY2021 · CA · contact PI
GI Cancer Genetics Research Program$53,114
P30 · FY2021 · CA · contact PI
Case GI SPORE$2,375,000
P50 · FY2020 · CA · contact PI
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma$1,289,211
U54 · FY2020 · CA
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment$951,000
R35 · FY2020 · CA · contact PI
Biomarkers for Reducing Mortality of Cancers of the Colon and Esophagus$757,530
U01 · FY2020 · CA · contact PI
Project 1: Targeting 15-PGDH in Colon Cancer Risk, Prevention and Treatment$403,790
P50 · FY2020 · CA · contact PI
Administrative Core$286,084
P50 · FY2020 · CA · contact PI
Project 2 - Molecular Markers for Barrett's Screening and Surveillance$283,011
U54 · FY2020 · CA · contact PI
GI Cancer Genetics Research Program$51,030
P30 · FY2020 · CA · contact PI
Case GI SPORE$2,325,000
P50 · FY2019 · CA · contact PI
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma$1,492,810
U54 · FY2019 · CA
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment$922,470
R35 · FY2019 · CA · contact PI
Biomarkers for Reducing Mortality of Cancers of the Colon and Esophagus$788,470
U01 · FY2019 · CA · contact PI
Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation$490,048
R01 · FY2019 · CA
Project 1: Targeting 15-PGDH in Colon Cancer Risk, Prevention and Treatment$412,659
P50 · FY2019 · CA · contact PI
Project 2 - Molecular Markers for Barrett's Screening and Surveillance$326,265
U54 · FY2019 · CA · contact PI
Administrative Core$300,672
P50 · FY2019 · CA · contact PI
GI Cancer Genetics Research Program$49,491
P30 · FY2019 · CA · contact PI
Case GI SPORE$2,500,000
P50 · FY2018 · CA · contact PI
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma$1,283,594
U54 · FY2018 · CA
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment$951,000
R35 · FY2018 · CA · contact PI
Biomarkers for Reducing Mortality of Cancers of the Colon and Esophagus$706,863
U01 · FY2018 · CA · contact PI
Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation$505,206
R01 · FY2018 · CA
Project 1: Targeting 15-PGDH in Colon Cancer Risk, Prevention and Treatment$446,891
P50 · FY2018 · CA · contact PI
Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation$401,377
R01 · FY2018 · CA
Administrative Core$323,215
P50 · FY2018 · CA · contact PI
Project 2 - Molecular Markers for Barrett's Screening and Surveillance$294,990
U54 · FY2018 · CA · contact PI
GI Cancer Genetics Research Program$50,794
P30 · FY2018 · CA · contact PI
GI Cancer Genetics Research Program$9,258
P30 · FY2018 · CA · contact PI
Case GI SPORE$2,375,000
P50 · FY2017 · CA · contact PI
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma$1,356,322
U54 · FY2017 · CA
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment$951,000
R35 · FY2017 · CA · contact PI
Biomarkers for Reducing Mortality of Cancers of the Colon and Esophagus$596,898
U01 · FY2017 · CA · contact PI
Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation$520,706
R01 · FY2017 · CA
Project 1: Targeting 15-PGDH in Colon Cancer Risk, Prevention and Treatment$424,707
P50 · FY2017 · CA · contact PI
Project 2 - Molecular Markers for Barrett's Screening and Surveillance$361,855
U54 · FY2017 · CA · contact PI
Administrative Core$306,470
P50 · FY2017 · CA · contact PI
Case GI SPORE$1,100,000
P50 · FY2016 · CA · contact PI
Biomarkers for Reducing Mortality of Cancers of the Colon and Esophagus$617,094
U01 · FY2016 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$462,954
U54 · FY2016 · CA
Role of gene enhancer elements in colon cancer$296,923
R01 · FY2016 · CA
Case GI SPORE$2,184,997
P50 · FY2015 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,446,550
U54 · FY2015 · CA
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and Prevention$399,909
P50 · FY2015 · CA · contact PI
Non-Coding and Coding RNAs as Biomarkers of Cancer Risk in Barrett's Esophagus$384,401
U54 · FY2015 · CA · contact PI
Role of gene enhancer elements in colon cancer$312,166
R01 · FY2015 · CA
Administration$219,926
P50 · FY2015 · CA · contact PI
Identify and validate novel epigenetic molecular markers for colorectal neoplasm$183,131
U01 · FY2015 · CA
Developmental Research Program$66,867
P50 · FY2015 · CA
Case GI SPORE$2,162,001
P50 · FY2014 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,424,703
U54 · FY2014 · CA
Identify and validate novel epigenetic molecular markers for colorectal neoplasm$520,108
U01 · FY2014 · CA
Non-Coding and Coding RNAs as Biomarkers of Cancer Risk in Barrett's Esophagus$429,252
U54 · FY2014 · CA · contact PI
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and Prevention$395,641
P50 · FY2014 · CA · contact PI
Role of gene enhancer elements in colon cancer$394,819
R01 · FY2014 · CA
Administration$185,326
P50 · FY2014 · CA · contact PI
Developmental Research Program$65,799
P50 · FY2014 · CA
Case GI SPORE$2,150,501
P50 · FY2013 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,268,396
U54 · FY2013 · CA
Identifying Inborn Genetic Susceptibility to Development of Cancer Metastasis$956,608
R01 · FY2013 · CA · contact PI
Identify and validate novel epigenetic molecular markers for colorectal neoplasm$516,256
U01 · FY2013 · CA
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and Prevention$411,456
P50 · FY2013 · CA · contact PI
Non-Coding and Coding RNAs as Biomarkers of Cancer Risk in Barrett's Esophagus$388,512
U54 · FY2013 · CA · contact PI
Role of gene enhancer elements in colon cancer$382,609
R01 · FY2013 · CA
Administration$180,256
P50 · FY2013 · CA · contact PI
Developmental Research Program$55,581
P50 · FY2013 · CA
Case GI SPORE$2,250,301
P50 · FY2012 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,174,448
U54 · FY2012 · CA
Identifying Inborn Genetic Susceptibility to Development of Cancer Metastasis$970,906
R01 · FY2012 · CA · contact PI
Identify and validate novel epigenetic molecular markers for colorectal neoplasm$566,328
U01 · FY2012 · CA
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and Prevention$419,743
P50 · FY2012 · CA · contact PI
Role of gene enhancer elements in colon cancer$393,999
R01 · FY2012 · CA
Non-Coding and Coding RNAs as Biomarkers of Cancer Risk in Barrett's Esophagus$365,347
U54 · FY2012 · CA · contact PI
Administration$188,572
P50 · FY2012 · CA · contact PI
New Familial Colon Cancer Gene Discovery Via Combined Linkage and SNP Association$107,435
R01 · FY2012 · CA · contact PI
Developmental Research Program$69,045
P50 · FY2012 · CA
Case GI SPORE$2,140,500
P50 · FY2011 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,026,258
U54 · FY2011 · CA
Identifying Inborn Genetic Susceptibility to Development of Cancer Metastasis$973,774
R01 · FY2011 · CA · contact PI
New Familial Colon Cancer Gene Discovery Via Combined Linkage and SNP Association$602,379
R01 · FY2011 · CA · contact PI
Identify and validate novel epigenetic molecular markers for colorectal neoplasm$584,114
U01 · FY2011 · CA
15-PGDH, A Novel in Vivo Suppressor of Colon Neoplasia in Mouse and Man$424,594
R01 · FY2011 · CA · contact PI
Identifying Inborn Genetic Susceptibility to Development of Cancer Metastasis$915,253
R01 · FY2010 · CA · contact PI
New Familial Colon Cancer Gene Discovery Via Combined Linkage and SNP Association$624,437
R01 · FY2010 · CA · contact PI
Identify and validate novel epigenetic molecular markers for colorectal neoplasm$462,017
U01 · FY2010 · CA
15-PGDH, A Novel in Vivo Suppressor of Colon Neoplasia in Mouse and Man$439,285
R01 · FY2010 · CA · contact PI
Identifying Inborn Genetic Susceptibility to Development of Cancer Metastasis$827,327
R01 · FY2009 · CA · contact PI
Obesity and Dietary Pathways Leading to Colon Cancer$714,291
U54 · FY2009 · CA · contact PI
New Familial Colon Cancer Gene Discovery Via Combined Linkage and SNP Association$615,656
R01 · FY2009 · CA · contact PI
15-PGDH, A Novel in Vivo Suppressor of Colon Neoplasia in Mouse and Man$432,248
R01 · FY2009 · CA · contact PI
15-PGDH, A Novel in Vivo Suppressor of Colon Neoplasia in Mouse and Man$310,860
R01 · FY2009 · CA · contact PI
Novel Molecular Markers of Human Colon Neoplasia$239,656
R01 · FY2009 · CA · contact PI
Obesity and Dietary Pathways Leading to Colon Cancer$617,280
U54 · FY2008 · CA · contact PI
New Familial Colon Cancer Gene Discovery Via Combined Linkage and SNP Association$598,266
R01 · FY2008 · CA · contact PI
15-PGDH, A Novel in Vivo Suppressor of Colon Neoplasia in Mouse and Man$398,846
R01 · FY2008 · CA · contact PI
Novel Molecular Markers of Human Colon Neoplasia$239,656
R01 · FY2008 · CA · contact PI
Obesity and Dietary Pathways Leading to Colon Cancer$613,274
U54 · FY2007 · CA · contact PI
15-PGDH, A Novel in Vivo Suppressor of Colon Neoplasia in Mouse and Man$351,687
R01 · FY2007 · CA · contact PI
PROGRAM LEADERS$242,667
P30 · FY2007 · CA · contact PI
Novel Molecular Markers of Human Colon Neoplasia$239,656
R01 · FY2007 · CA · contact PI
OBESITY AND MOLECULAR PATHWAYS LEADING TO COLON CANCER$5,145
P41 · FY2007 · RR · contact PI
Obesity and Dietary Pathways Leading to Colon Cancer$350,017
U54 · FY2006 · CA · contact PI
Novel Molecular Markers of Human Colon Neoplasia$246,814
R01 · FY2006 · CA · contact PI
NOVEL MUTATOR PHENOTYPES IMPORTANT IN HUMAN COLON CANCER$561,054
R01 · FY2005 · CA
Obesity and Dietary Pathways Leading to Colon Cancer$340,805
U54 · FY2005 · CA
SUSCEPTIBILITY GENES FOR HUMAN COLON NEOPLASIA$141,026
U01 · FY2005 · CA
GENE EXPRESSION OF COLON CANCERS THAT METASTASIZE$1,593,214
U01 · FY2004 · CA
NOVEL MUTATOR PHENOTYPES IMPORTANT IN HUMAN COLON CANCER$546,082
R01 · FY2004 · CA
GENE EXPRESSION OF COLON CANCERS THAT METASTASIZE$1,511,167
U01 · FY2003 · CA
SUSCEPTIBILITY GENES FOR HUMAN COLON NEOPLASIA$1,108,972
U01 · FY2003 · CA
NOVEL MUTATOR PHENOTYPES IMPORTANT IN HUMAN COLON CANCER$484,500
R01 · FY2003 · CA
GENE EXPRESSION OF COLON CANCERS THAT METASTASIZE$1,471,376
U01 · FY2002 · CA
SUSCEPTIBILITY GENES FOR HUMAN COLON NEOPLASIA$1,074,783
U01 · FY2002 · CA
NOVEL MUTATOR PHENOTYPES IMPORTANT IN HUMAN COLON CANCER$452,385
R01 · FY2002 · CA
GENE EXPRESSION OF COLON CANCERS THAT METASTASIZE$1,429,417
U01 · FY2001 · CA
SUSCEPTIBILITY GENES FOR HUMAN COLON NEOPLASIA$897,208
U01 · FY2001 · CA
NOVEL MUTATOR PHENOTYPES IMPORTANT IN HUMAN COLON CANCER$439,209
R01 · FY2001 · CA
LINKAGE STUDY OF COLORECTAL POLYPS &CANCER: FAMILIAL CORRELATION$294,555
P41 · FY2001 · RR
SUSCEPTIBILITY GENES FOR HUMAN COLON NEOPLASIA$873,156
U01 · FY2000 · CA
GENE EXPRESSION OF COLON CANCERS THAT METASTASIZE$718,093
U01 · FY2000 · CA
TGF-B RECEPTOR GENE MUTATIONS DETECTED IN HUMAN CANCER$435,998
R01 · FY2000 · CA
NOVEL MUTATOR PHENOTYPES IMPORTANT IN HUMAN COLON CANCER$413,378
R01 · FY2000 · CA
LINKAGE STUDY OF COLORECTAL POLYPS &CANCER: FAMILIAL CORRELATION$7,508
P41 · FY2000 · RR